Previous close | 20.63 |
Open | 20.58 |
Bid | 20.63 x N/A |
Ask | 20.72 x N/A |
Day's range | 20.58 - 20.58 |
52-week range | 15.37 - 20.98 |
Volume | |
Avg. volume | 114 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 31 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
The latest investor updates on stocks that are trending on Friday.
The move separates the companies after a carve-up twoo years ago that saw GSK spin off and float its consumer arm as Haleon, amid fears the division was weighing on the growth of its dedicated healthcare business.